The inequities in access to healthcare documented and experienced by Indigenous peoples in Canada are startling given Canada's publicly funded and 'equally accessible' healthcare system, however little is known about access to cancer care, and barriers to accessing cancer care in particular. We conducted a scoping review to identify what is known about barriers to accessing cancer care among Indigenous peoples in Canada (including barriers to accessing cancer services, and barriers to receiving optimal care once those services were accessed), and to identify where along the cancer continuum (screening, diagnosis, treatment, etc.) these barriers are located. We searched SCOPUS, EBSCOhost, Google Scholar, Ovid MEDLINE and Ovid EMBASE for studies published between 1996 and 2019 that examined access to cancer care for Indigenous peoples in Canada; 36 studies were included in our analysis. Our review indicates that Indigenous peoples face barriers to accessing care at the individual level (factors at the level of the individual patient or healthcare provider (HCP) that impede access to cancer care), at the systems level (factors stemming from the healthcare system and its structure), and at the structural level (factors that are embedded within and systematically produced political, historical, social or economic structures). While barriers to accessing cancer care were found throughout the trajectory, there remains a disproportionate focus on access to cancer screening. Moreover, some barriers to accessing cancer care, such as racism, discrimination and lack of culturally safe care, although rooted in structural factors, were inconsistently framed as individual and/or systems factors. This suggests that while there is growing awareness of the impact that racism and discrimination have on access to cancer care at the individual level for example, there remains a lack of understanding of how these issues are linked with systemic and structural issues.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.socscimed.2019.112495 | DOI Listing |
Cytotherapy
January 2025
Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.
View Article and Find Full Text PDFCancer Biol Ther
December 2025
Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
Adaptive immune resistance in cancer describes the various mechanisms by which tumors adapt to evade anti-tumor immune responses. IFN-γ induction of programmed death-ligand 1 (PD-L1) was the first defined and validated adaptive immune resistance mechanism. The endoplasmic reticulum (ER) is central to adaptive immune resistance as immune modulatory secreted and integral membrane proteins are dependent on ER.
View Article and Find Full Text PDFPort J Card Thorac Vasc Surg
January 2025
Thoracic surgeon, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
The use of extracorporeal membrane oxygenation (ECMO) in surgery is expanding as the medical community started adopting it, with good results, for procedures with high risk of respiratory and hemodynamic instability. This technique provided the possibility to reduce the number of patients previously considered inoperable because of these limitations. Thymic epithelial tumors (TETs) are rare neoplastic mediastinal lesions, with a reported incidence of 0.
View Article and Find Full Text PDFActa Derm Venereol
January 2025
Department of Dermatology, Saint-André Hospital, Bordeaux University Hospital, Bordeaux, France.
The objective of this retrospective observational study was to estimate the prevalence of actinic keratosis (AK) in individuals aged ≥ 40 years in France, to describe the characteristics of affected patients, and to describe treatments. A representative panel of 20,000 households with ≥ 1 member aged ≥ 40 years were invited to participate. Participants who reported AK lesions diagnosed by a physician were eligible.
View Article and Find Full Text PDFJ Infect Dev Ctries
December 2024
The Cancer Hospital Affiliated to Shandong First Medical University (Shandong Cancer Prevention Research Institute, Shandong Cancer Hospital), Jinan 250117, China.
Introduction: In this study, we analyzed the psychological aspects of coronavirus disease 2019 (COVID-19) patients who were discharged from the hospitals in Shanghai, China, and later had positive nucleic acid retest results for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant infection (re-positive COVID-19). The purpose was to gain clarity on the patients' needs and to provide evidence for the medical staff to deliver scientific and targeted health care to the patients.
Methodology: We screened patients who tested positive for SARS-CoV-2 Omicron variant infection by nucleic acid testing after having previously recovered from a COVID-19 infection and being discharged from Shanghai shelter hospitals or COVID-19-designated hospitals from April 3, 2022, to May 10, 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!